← FDA DRUG APPROVALS

FDA ANDA · ANDA204994

LACOSAMIDE

Sponsor: AUROBINDO PHARMA LTD

APPLICATION
ANDA204994
TYPE
ANDA
ORIGINAL APPROVAL
2023-01-05
LATEST ACTION
2026-05-22
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

LACOSAMIDEPrescription
LACOSAMIDE 200MG · TABLET · ORAL
LACOSAMIDEPrescription
LACOSAMIDE 100MG · TABLET · ORAL
LACOSAMIDEPrescription
LACOSAMIDE 150MG · TABLET · ORAL
LACOSAMIDEPrescription
LACOSAMIDE 50MG · TABLET · ORAL

Approval history

2026-05-22Labeling · Supplement 9 · standardAP
2024-11-15Labeling · Supplement 6 · standardAP
2024-11-15Labeling · Supplement 4 · standardAP
2024-11-15Labeling · Supplement 5 · standardAP
2024-11-15Labeling · Supplement 3 · standardAP
2023-01-05UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →